of enzymes or proteins. The specificity of TFO binding to the target relies on the hydrogen bonds formed between the TFO (third strand) and the purine-rich strand of the target duplex. Gene conversion or gene repair has been shown using a "bifunctional TFO," a DNA molecule 
distinct, techniques. This criticism, however, was based on the incorrect assumption that the entire process was catalyzed by the homologous recombination enzyme machinery, a protein-driven pathway that operates very inefficiently in mammalian cells and acts to exchange homologous DNA fragments through genomic integration. Recent data from eukaryotic model systems, however, supports the original proposal (see Rice et al., 2001 , and references therein) that homologous recombination is not the central process in gene repair and that genomic integration of the chimera does not occur. Furthermore, the original reports ; ColeStrauss et al., 1996) indicated that the conditions for gene repair are likely to differ from cell line to cell line and that the efficiency with which the vector enters the cell is an absolutely critical parameter and must be optimized in each case.
The first confirmation of the technique came from experiments in which nucleotide exchange was attempted in the alkaline phosphatase gene of cultured human HuH-7 cells (Kren et al., 1997) and in factor IX gene of rat hepatocytes in vivo (Kren et al., 1998) . These workers focused most of their efforts on optimizing the uptake of the vectors into liver cells first and then succeeded in observing high levels of gene repair. Subsequent work in the Gunn rat model for Crigler-Najjar syndrome (liver cell targeting) (Kren et al., 1999) was the first to demonstrate a clinically relevant response to gene repair activity, due in large part to the optimized method of vector delivery. In this case, the chimeric oligonucleotides coupled to a liposomal transfer agent were injected intravenously, a strategy ensuring that a high percentage of the oligonucleotide will localize to the liver. Using a similar delivery strategy, Bartlett optimized for these cellular systems enabling high levels of repair. Thus, delivery of sufficient levels of vector to the target cells as well as the quality and percentage of episomal and chromosomal (Colefull-length synthetic vector in the sample are requireStrauss et al., 1996) levels. In the latter case, the mutaments for achieving detectable levels of gene repair. tion responsible for sickle cell anemia, a single A→T Gene Repair with Single-Stranded DNA. During the base mutation in the sixth codon of the ␤ S -globin coding last several years, our lab has developed a targeting region, was corrected in a model cell line. Conversion vector that uses a simplified mode of synthesis and is was detected by RFLP analysis, Southern blots, and capable of directing comparable levels of gene repair DNA sequencing with a frequency greater than 1%.
relative to the chimera. This was accomplished by taking These initial reports were met with some skepticism a reductionist approach to elucidating the mechanism because the number of cells exhibiting the targeted geof the repair reaction, which led to the functional defininetic change was several logs higher than the frequency tion of the DNA and RNA strands comprising the doublestranded vector (Gamper et al., 2000a) . Each part of the reported by previously established, but mechanistically causes an expansion of the polyglutamine tract in the huntingtin protein (Wexler et al., 1987) . The resulting "gain of function" mediates the clinical and pathological sequelae of HD, although the mechanism by which this occurs is only beginning to be understood. Neuropathologically, the most striking changes occur in the caudate nucleus and putamen, where the medium spiny neurons are particularly vulnerable. In diseases such as Parkinson's or Alzheimer's, identification of patients prior to the onset of symptoms cannot be made with certainty, and extensive neurodegeneration has to occur prior to the initiation of clinical symptoms. In contrast, in Huntington's disease early detection permits the identification of individuals destined to develop the disease and early intervention is possible.
Altering a CAG to a CTG using a gene repair vector would produce an interrupted codon repeat and this altered sequence might translate into a protein that is less likely to catalyze aggregate formation or persistence. Single-stranded vectors could also be used to create a stop codon (CAG→TAG) within the coding region of one huntingtin gene. This would reduce the population of huntingtin proteins participating in aggregate formation and, perhaps, produce a dominant-negative protein. Alternatively, the expansion potential of interrupted triplet re- vector to the target tissue. In vivo administration will Hence, an important advance toward elevating frequenrequire direct injection into the brain or use of a peristalcies of gene repair has simply involved the development tic pump implanted in the patient that can perfuse brain of a more elemental vector design, one that was easier cells. Ex vivo approaches might include the electroporato produce as a full-length molecule (Figure 2) . tion or transformation of neurons or neuronal stem cells Genetic Repair of Neurodegenerative Disorders. Neuisolated from the patient and then reintroduced, combinrodegenerative disorders with characterized genetic ing the clinical strategies of gene therapy and cell components could conceivably be treated with stratetherapy. gies involving these types of oligonucleotides. At presThe specific repair of mutations within the context of ent, the most appropriate target may be Huntington's the chromosome would provide a novel way to treat disease (HD). Huntington's disease is an autosomal hereditary diseases, especially for neurodegenerative dominant, fully penetrant, neurodegenerative disease disorders. One advantage of using synthetic oligonucleotide vectors is that they are small molecules that could resulting from a single mutation in the gene, which be designed to penetrate blood-brain barriers more easily than their viral counterparts. Many viral-based agents induce an immune response and carry a limited therapeutic cDNA payload. The expression of these "cDNA viral vectors" is ultimately destined to be turned off by various processes, including methylation. Thus, subsequent and recurrent administration, which increases the probability of an immune response, will be required. One advantage of the gene repair process is that any auxiliary gene coinjected to increase the activity of the synthetic vector would only be required transiently; hence, reducing the probability of immune responses due to a repeated dosage schedule. By far, however, the most daunting problem surrounding gene repair for neurodegenerative diseases will be managing expectations in the field of gene therapy that has been plagued by diminishing returns.
